

WORLDWIDE REGISTRATION

Dolutegravir 5 mg Dispersible Tablets

APPROVAL

Argentina	Ghana	Trinidad & Tobago
Australia	Israel	Turkey
Botswana	Kazakhstan	Uganda
Brazil	Kenya	UK
Cameroon	Malawi	Uruguay
Canada	Mexico	USA
Chile	Namibia	Uzbekistan
China	Niger	Zambia
Colombia	Peru	Zimbabwe
Cote d'Ivoire	Singapore	
DRC	South Africa	
Ecuador	Switzerland	
EU	Tanzania	
Gabon	Thailand	

SUBMISSION

Burkina Faso	Nigeria
China	Senegal
Egypt	UAE
Ethiopia	Ukraine
Malaysia	
Mozambique	

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ "Submission" means: A registration dossier has been submitted to local authority for review in the relevant country. Please note, Submission does not guarantee that a Marketing Authorisation will be granted.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 29 May 2024 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.